• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 SEER 数据库的髓样甲状腺癌总生存预测列线图模型的建立与验证

The Establishment and Verification of a Nomogram Model for Predicting the Overall Survival of Medullary Thyroid Carcinoma: An Analysis Based on the SEER Database.

机构信息

Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.

Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.

出版信息

Curr Oncol. 2023 Dec 22;31(1):84-96. doi: 10.3390/curroncol31010006.

DOI:10.3390/curroncol31010006
PMID:38248091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10814845/
Abstract

(1) Background: This study aimed to establish a nomogram model for predicting the overall survival (OS) of medullary thyroid carcinoma (MTC) patients based on the Surveillance, Epidemiology, and End Results (SEER) database. (2) Methods: Patients with MTC in the SEER database from 2004 to 2015 were included and divided into a modeling group and an internal validation group. We also selected MTC patients from our center from 2007 to 2019 to establish an external validation group. Univariate and multivariate Cox regression analyses were used to screen for significant independent variables and to establish a nomogram model. Kaplan-Meier (K-M) curves were plotted to evaluate the influence of the predictors. The C-indexes, areas under the curves (AUCs), and calibration curves were plotted to validate the predictive effect of the model. (3) Results: A total of 1981 MTC patients from the SEER database and 85 MTC patients from our center were included. The univariate and multivariate Cox regression analyses showed that age, tumor size, N stage, and M stage were significant factors, and a nomogram model was established. The C-index of the modeling group was 0.792, and the AUCs were 0.811, 0.825, and 0.824. The C-index of the internal validation group was 0.793, and the AUCs were 0.847, 0.846, and 0.796. The C-index of the external validation group was 0.871, and the AUCs were 0.911 and 0.827. The calibration curves indicated that the prediction ability was reliable. (4) Conclusions: A nomogram model based on age, tumor size, N stage, and M stage was able to predict the OS of MTC patients.

摘要

(1) 背景:本研究旨在基于监测、流行病学和最终结果(SEER)数据库建立预测甲状腺髓样癌(MTC)患者总生存期(OS)的列线图模型。

(2) 方法:纳入 SEER 数据库中 2004 年至 2015 年的 MTC 患者,分为建模组和内部验证组。还从我们中心选择了 2007 年至 2019 年的 MTC 患者,建立外部验证组。采用单因素和多因素 Cox 回归分析筛选显著的独立变量,并建立列线图模型。绘制 Kaplan-Meier(K-M)曲线评估预测因素的影响。绘制 C 指数、曲线下面积(AUC)和校准曲线以验证模型的预测效果。

(3) 结果:共纳入 SEER 数据库中的 1981 例 MTC 患者和我们中心的 85 例 MTC 患者。单因素和多因素 Cox 回归分析显示,年龄、肿瘤大小、N 分期和 M 分期是显著因素,并建立了列线图模型。建模组的 C 指数为 0.792,AUC 分别为 0.811、0.825 和 0.824。内部验证组的 C 指数为 0.793,AUC 分别为 0.847、0.846 和 0.796。外部验证组的 C 指数为 0.871,AUC 分别为 0.911 和 0.827。校准曲线表明预测能力可靠。

(4) 结论:基于年龄、肿瘤大小、N 分期和 M 分期的列线图模型能够预测 MTC 患者的 OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/58e56f375c90/curroncol-31-00006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/00e2228e7b83/curroncol-31-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/05b00e905a21/curroncol-31-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/cd0981eab184/curroncol-31-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/58e56f375c90/curroncol-31-00006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/00e2228e7b83/curroncol-31-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/05b00e905a21/curroncol-31-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/cd0981eab184/curroncol-31-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f38/10814845/58e56f375c90/curroncol-31-00006-g004.jpg

相似文献

1
The Establishment and Verification of a Nomogram Model for Predicting the Overall Survival of Medullary Thyroid Carcinoma: An Analysis Based on the SEER Database.基于 SEER 数据库的髓样甲状腺癌总生存预测列线图模型的建立与验证
Curr Oncol. 2023 Dec 22;31(1):84-96. doi: 10.3390/curroncol31010006.
2
Establishment and validation of a nomogram model for predicting distant metastasis in medullary thyroid carcinoma: An analysis of the SEER database based on the AJCC 8th TNM staging system.建立并验证基于 AJCC 第 8 版 TNM 分期系统的 SEER 数据库预测甲状腺髓样癌远处转移的列线图模型。
Front Endocrinol (Lausanne). 2023 Feb 15;14:1119656. doi: 10.3389/fendo.2023.1119656. eCollection 2023.
3
Development and validation of a nomogram to predict overall survival in patients with redefined anaplastic thyroid carcinoma based on the SEER database.基于 SEER 数据库构建并验证预测重新定义的间变性甲状腺癌患者总生存的列线图。
Int J Clin Oncol. 2024 Jun;29(6):744-754. doi: 10.1007/s10147-024-02495-2. Epub 2024 Apr 7.
4
Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.基于 SEER 数据库分析建立低分化甲状腺癌患者癌症特异性生存的列线图模型并验证
Front Endocrinol (Lausanne). 2022 Sep 13;13:882279. doi: 10.3389/fendo.2022.882279. eCollection 2022.
5
The Nomogram predicting the overall survival of patients with pancreatic cancer treated with radiotherapy: a study based on the SEER database and a Chinese cohort.基于 SEER 数据库和中国队列研究的列线图预测胰腺癌患者放疗后总生存的研究。
Front Endocrinol (Lausanne). 2023 Oct 25;14:1266318. doi: 10.3389/fendo.2023.1266318. eCollection 2023.
6
Construction and Validation of a Nomogram Based on the Log Odds of Positive Lymph Nodes to Predict the Prognosis of Medullary Thyroid Carcinoma After Surgery.基于阳性淋巴结对数优势构建并验证列线图预测甲状腺髓样癌术后预后
Ann Surg Oncol. 2021 Aug;28(8):4360-4370. doi: 10.1245/s10434-020-09567-3. Epub 2021 Jan 19.
7
A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.基于 SEER 数据库和中国队列的人群研究:用于预测接受外照射放射治疗的肝细胞癌患者总生存期的基于网络的列线图模型。
Front Endocrinol (Lausanne). 2023 Jan 31;14:1070396. doi: 10.3389/fendo.2023.1070396. eCollection 2023.
8
The Prediction of Metastases of Lateral Cervical Lymph Node in Medullary Thyroid Carcinoma.甲状腺髓样癌颈侧区淋巴结转移的预测。
Front Endocrinol (Lausanne). 2021 Nov 17;12:741289. doi: 10.3389/fendo.2021.741289. eCollection 2021.
9
[Establishment of a prognostic nomogram and discussion on optimal treatment for cervical adenocarcinoma:a retrospective study based on SEER database and Chinese single-center data].[建立预后列线图并探讨宫颈腺癌的最佳治疗方案:一项基于SEER数据库和中国单中心数据的回顾性研究]
Zhonghua Fu Chan Ke Za Zhi. 2024 Apr 25;59(4):307-319. doi: 10.3760/cma.j.cn112141-20231101-00172.
10
Development and validation of survival nomograms for patients with differentiated thyroid cancer with distant metastases: a SEER Program-based study.基于 SEER 计划的研究:分化型甲状腺癌伴远处转移患者生存列线图的建立与验证。
J Endocrinol Invest. 2024 Jan;47(1):115-129. doi: 10.1007/s40618-023-02129-w. Epub 2023 Jun 9.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
A nomogram to predict lateral lymph node metastases in lateral neck in patients with medullary thyroid cancer.用于预测甲状腺髓样癌患者侧颈部侧方淋巴结转移的列线图。
Front Endocrinol (Lausanne). 2022 Aug 16;13:902546. doi: 10.3389/fendo.2022.902546. eCollection 2022.
3
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.LIBRETTO-531 研究:塞普替尼在初治多激酶抑制剂-naïve 型突变型甲状腺髓样癌中的 III 期研究。
Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15.
4
Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma.肿瘤分级可预测降钙素倍增时间和髓样甲状腺癌切除后的疾病特异性结局。
Thyroid. 2022 Oct;32(10):1193-1200. doi: 10.1089/thy.2022.0217. Epub 2022 Sep 20.
5
RET kinase inhibitors for -altered thyroid cancers.用于RET基因改变的甲状腺癌的RET激酶抑制剂。
Ther Adv Med Oncol. 2022 Jun 21;14:17588359221101691. doi: 10.1177/17588359221101691. eCollection 2022.
6
Metastatic medullary thyroid carcinoma: a new way forward.转移性甲状腺髓样癌:新的前进方向。
Endocr Relat Cancer. 2022 May 31;29(7):R85-R103. doi: 10.1530/ERC-21-0368.
7
Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.利用循环肿瘤标志物进行甲状腺髓样癌的诊断和管理。
Pathol Res Pract. 2022 Jan;229:153694. doi: 10.1016/j.prp.2021.153694. Epub 2021 Nov 24.
8
Medullary thyroid carcinoma.甲状腺髓样癌。
Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):540-546. doi: 10.1097/MED.0000000000000662.
9
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With Gene Mutations or Fusions.美国食品药品监督管理局批准概要:普拉替尼用于治疗携带基因突变或融合的肺癌和甲状腺癌。
Clin Cancer Res. 2021 Oct 15;27(20):5452-5456. doi: 10.1158/1078-0432.CCR-21-0967. Epub 2021 May 27.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.